If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
81
results.
Updated on
21/02/2026 [06:45:00]
Absstract of: WO2026039717A1
Pharmaceutical compositions and compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized an RNA aptamer are useful in methods of treating cancer (such as leukemia) and methods of inhibiting DNA methyltransferase. In embodiments, the RNA aptamer binds to an intracellular target such as DNMT1, NF-kB, RUNX1, MYC, MYB, ETS, PAX5, MDM2, F0XM1, PU.l, STAT3, STATS. STAT6, FAD, ATP5B, or beta-catenin.
Absstract of: WO2026036217A1
A peptide construct for targeting PDGFRA includes diagnostic or therapeutic moiety which includes a chelator and a radionuclide. Also disclosed are diagnostic and therapeutic methods using the peptide constructs for diagnosing, imaging or treating cancer, particularly carcinoma of the thyroid, GIST, colon, breast, sarcoma, glioblastoma, or lymphoma.
Absstract of: US20260049279A1
The invention features polypeptides and/or transgenic effector cells including T cell receptors (TCRs) which specifically bind anaplastic lymphoma kinase (ALK) antigens or peptide sequences, and the use of such polypeptides and/or transgenic effector cells and TCRs specific to anaplastic lymphoma kinase (ALK) antigens or peptide sequences in compositions and methods for treating ALK-positive neoplasias such as Non-Small Cell Lung Cancers (NSCLCs).
Absstract of: US20260049134A1
The invention provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize a multiple myeloma cell surface antigen selected from PTPRG, CADM1, ICAM1, and GARS. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications for hematologic malignancies including multiple myeloma and acute myeloid leukemia (AML).
Absstract of: US20260048126A1
Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor.
Absstract of: AU2024332707A1
The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.
Absstract of: US20260048055A1
Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.
Absstract of: MX2025012028A
The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).
Absstract of: GB2643430A
A combination for use in treating cancer comprising: (a) a compound of Formula I or a pharmaceutically acceptable salt thereof, and (b) a compound of Formula II or pharmaceutically acceptable salt thereof is provided: wherein R1 is a branched or linear C2-C5 alkyl group optionally functionalised with an amine, imidazole, alcohol or morpholine; R2 is selected from hydrogen or methyl; X1 is a hydrogen or methyl group; X2 is a cyclic group as defined herein, or X1 and X2 together with the N atom form a heterocyclic group as defined herein; X3 is a hydrogen or halogen; and the olefin bond may be either in the (E)- or (Z)-configuration. The cancer may be cervical cancer, oesophageal cancer, ovarian cancer, uterine cancer, breast cancer or multiple myeloma. The compound of Formula I is an inhibitor of the nuclear import transport receptor Karyopherin Beta 1 (Kpnβ1, Importin β) such as INI-43. The compound of Formula II is an inhibitor of the nuclear export transport receptor Chromosome Maintenance 1 (Crm1, Exportin 1, XPO1) such as Selinexor (XPOVIO, KPT-330).
Absstract of: WO2024213782A1
The present invention relates to the combination of anti-CD3 agent, in particular monoclonal antibody, with immunotherapeutic agents, and its use in oncology, for treating T Cell Acute Lymphoblastic Leukemia (T-ALL). The invention also relates to a pharmaceutical composition comprising said combination and the use of said combination to induce cell death of T-ALL cells.
Absstract of: WO2026032322A1
Disclosed in the present application is the use of a compound of formula I in the preparation of a drug for treating the following tumors, which are selected from gastric cancer, esophageal cancer, cholangiocarcinoma, nasopharyngeal cancer, soft tissue sarcoma, prostate cancer, liver cancer, non-small cell lung cancer, breast cancer, glioma, leukemia, ovarian cancer, cervical cancer, endometrial carcinoma, primary brain tumors, brain metastatic tumors, pancreatic cancer and angiosarcoma. Further disclosed is the use of the compound in combination with other anti-tumor drugs in the treatment of the above-mentioned cancers.
Absstract of: WO2026030836A1
Use of Placenta Hominis in the preparation of an anti-cancer drug. Water extraction is one of extraction methods for Placenta Hominis. Placenta Hominis can treat various cancers, such as lymphoma, leukemia, skin cancer, lung cancer, breast cancer, liver cancer, gastric cancer, pancreatic cancer, rectal cancer, brain cancer, kidney cancer, bladder cancer, etc., by improving human immunity.
Absstract of: US20260042776A1
The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity:wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
Absstract of: US20260041768A1
Provided herein are methods of treating cancer in a subject in need thereof by administering an anti-BCMA CAR-T cell and a GPRC5D×CD3 bispecific antibody. In some embodiments, the subject has relapsed and/or refractory multiple myeloma. In some embodiments, the subject has received at least one prior line of therapy. In some embodiments, the subject has newly diagnosed multiple myeloma and is transplant ineligible.
Absstract of: US20260041719A1
This document relates to methods and materials involved in assessing and/or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.
Absstract of: WO2026033458A1
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.
Absstract of: US20260041647A1
Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and/or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and/or an autoimmune diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and/or other targets in subject.
Absstract of: US20260042853A1
IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25.sup.+ and/or CCR4.sup.+ cutaneous T cell lymphoma, and other human CD25.sup.+ or CCR4.sup.+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25.sup.+ or CCR4.sup.+ Tregs.
Absstract of: US20260042835A1
This disclosure relates to methods for treating cancer in a subject identified as having chronic myelomonocytic leukemia (CMML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).
Absstract of: US20260042861A1
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.
Absstract of: US20260042752A1
Provided are compounds of the structural Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Absstract of: AU2024294949A1
Provided are methods of treating a subject having a hematologic malignancy or pre-malignancy that involve administering an effective amount of olutasidenib, venetoclax, and a hypomethylating agent. In some cases, the patient has an IDH1 mutation.
Absstract of: WO2026035999A1
Provided are compounds of the structural Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Absstract of: WO2026035974A1
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Nº publicación: EP4687923A1 11/02/2026
Applicant:
TAKEDA PHARMACEUTICALS CO [JP]
Takeda Pharmaceutical Company Limited
Absstract of: US20260034176A1
The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.
BOPI
Electronic site
